Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 1.00 |
| ▸ | CNR2 | P34972 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469259 | 1.00 | CNR1 (1.00) | CNR1CNR2MEN1RAB9AKMT2A | |
| SCHEMBL4911349 | 0.89 | CNR1 (0.80) | CNR1CNR2MEN1RAB9AKMT2A | |
| SCHEMBL20557634 | 0.88 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL30469231 | 0.88 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL30469267 | 0.86 | CNR1 (1.00) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL20557649 | 0.86 | CNR1 (1.00) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL20557298 | 0.84 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL30469269 | 0.84 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL9190814 | 0.84 | KMT2A (1.00) | CNR1MEN1RAB9AKMT2A | |
| SCHEMBL5186268 | 0.83 | CNR1 (0.69) | CNR1CNR2MEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2021-10-28 | — | — | US | claimed |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-27 | — | — | US | claimed |
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE | 2025-07-15 | — | — | US | disclosed |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2021-10-28 | — | — | US | disclosed |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3621951-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | Research Triangle Institute (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-27 | — | — | US | disclosed |
| WO-2018209030-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RTI INTERNATIONAL (US) | 2018-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885MEN1 3226/4885 |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885MEN1 3226/4885 |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885MEN1 3226/4885 |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885MEN1 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.